| SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| The Problem of TP53-Mutant MDS/AML |
|
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| New Approaches for Anemia in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Transfusion Support of Patients with Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53 |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Morphologic Characteristics of Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
